Impact of organic anion transporting polypeptide, P-glycoprotein, and breast cancer resistance protein transporters on observed tamoxifen and endoxifen concentration and adverse effects
The DOI matches its Crossref record; 46 of the 46 references it cites were found in a registry or an index.
Abstract
Objective: Drug transporters are important determinants of drug disposition and response. Tamoxifen is an antiestrogen for breast cancer therapy known for adverse drug reactions (ADRs). In this study, the involvement of OATP transporters in tamoxifen and endoxifen transport was studied in vitro while the impact of single nucleotide variation (SNV) in OATP and efflux transporters P-glycoprotein (ABCB1) and Breast Cancer Resistance Protein (ABCG2) on ADRs during tamoxifen therapy were assessed. Methods: Patients receiving tamoxifen for breast cancer, who were CYP2D6 normal metabolizers were enrolled (n = 296). Patients completed a survey that captured ADRs and a blood sample was collected. Tamoxifen and endoxifen plasma concentration were measured, while DNA was genotyped for SNVs in ABCB1, ABCG2, SLCO1A2, SLCO1B1, and SLCO2B1. HEK293T cells were used to determine the extent of OATP-mediated transport of tamoxifen and endoxifen. Results: Common SNVs of ABCB1, ABCG2, SLCO1A2, and SLCO1B1 were not associated with tamoxifen or endoxifen concentration. However, tamoxifen concentration was significantly higher in carriers of SLCO2B1 c.935G>A (129.8 ng/mL) compared to wildtype (114.9 ng/mL; P = 0.036). Interestingly, subjects who carried SLCO1A2 c.38A>G reported significantly less dizziness (P = 0.016). In-vitro analysis demonstrated increased cellular accumulation of tamoxifen in cells overexpressing OATP1A2 and 1B1, but endoxifen uptake was not effected in OATP overexpressing cells. Conclusions: We showed that OATP1A2, a transporter known to be expressed at the blood-brain barrier, is capable of tamoxifen transport. Additionally, OATP1A2 c.38A>G was associated with reduced ADRs. Taken together, our findings suggest genetic variation in OATP transporters may be an important predictor of tamoxifen ADRs.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Overexpression of epidermal growth factor receptor (EGFR), variations in TAM metabolism, and increased expression of drug-resistant proteins (P-glycoprotein, P-gp) all contribute to the development of TAM-resistant breast cancer.”
From Multifunctional and dual-targeting polymeric prodrug nanomicelles against tamoxifen-resistant breast cancer (2026) · cites this paper as [19]
Citations
Cites
Early Breast Cancer Trialists' Collaborative Group (EBCTCG) (2011) · The Lancet · doi:10.1016/s0140-6736(11)60993-8 · Cited by 3,075
Davies, C., Pan, H., Godwin, J., Gray, R., Arriagada, R., Raina, V., Abraham, M., Alencar, V. H. M., Badran, A., Bonfill, X., et al. (2013) · The Lancet · doi:10.1016/s0140-6736(12)61963-1 · Cited by 2,044
Goetz, M. P., Rae, J. M., Suman, V. J., Safgren, S. L., Ames, M. M., Visscher, D. W., Reynolds, C., Couch, F. J., Lingle, W. L., Flockhart, D. A., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.03.3266 · Cited by 791
Desta, Z., Ward, B. A., Soukhova, N. V., & Flockhart, D. A. (2004) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.104.065607 · Cited by 645
Schroth, W. (2009) · JAMA · doi:10.1001/jama.2009.1420 · Cited by 531
Schroth, W., Antoniadou, L., Fritz, P., Schwab, M., Muerdter, T., Zanger, U. M., Simon, W., Eichelbaum, M., & Brauch, H. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.12.2705 · Cited by 467
Methodologic lessons learned from hot flash studies.
Sloan, J. A., Loprinzi, C. L., Novotny, P. J., Barton, D. L., Lavasseur, B. I., & Windschitl, H. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.23.4280 · Cited by 462
Polymorphisms in Human Organic Anion-transporting Polypeptide 1A2 (OATP1A2)
Lee, W., Glaeser, H., Smith, L. H., Roberts, R. L., Moeckel, G. W., Gervasini, G., Leake, B. F., & Kim, R. B. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m411092200 · Cited by 365
Self-citationRegan, M. M., Leyland-Jones, B., Bouzyk, M., Pagani, O., Tang, W., Kammler, R., Dell’Orto, P., Biasi, M. O., Thürlimann, B., Lyng, M. B., et al. (2012) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djs125 · Cited by 339
Cited by
Ferri, N., Colombo, E., & Corsini, A. (2024) · Pharmaceutics · doi:10.3390/pharmaceutics16111371 · Cited by 27
Zhang, X. M., Feng, J., Cai, X., Weilang, X., Ding, T., He, M. Y., Dong, Y., Xu, X., & Ye, Z. (2026) · npj Precision Oncology · doi:10.1038/s41698-025-01198-9 · Cited by 11
Impact of Complex Genetic and Drug–Drug Interactions on Tamoxifen Metabolism and Efficacy
Saad, I., Bentayebi, K., Ettoury, S., Zarrik, O., Bourais, I., Boutayeb, S., Samer, C. F., Daali, Y., Eljaoudi, R., & Louati, S. (2025) · Journal of Personalized Medicine · doi:10.3390/jpm15110505 · Cited by 6
Molehin, O. R., & Afolabi, A. T. (2026) · Clinical & Translational Oncology · doi:10.1007/s12094-026-04227-6 · Cited by 3
Observed tamoxifen drug interactions are dependent on both CYP2D6 phenotype and inhibitor potency
Keller, D., Medwid, S. J., Legan, R. M., Schwarz, U. I., & Kim, R. B. (2025) · Journal of Pharmacy and Pharmacology · doi:10.1093/jpp/rgaf132 · Cited by 2
Self-citation
Metadata
- Authors
- Keller, D. N., Medwid, S. J., Ross, C. D., Wigle, T. J., & Kim, R. B.
- Affiliations
- London Health Sciences Centre (CA)
- Western University (CA)
- Corresponding author
- Kim, Richard B.
- Venue
- Pharmacogenetics and Genomics
- Published
- 2022-11-07
- Volume
- 33
- Issue
- 1
- Pages
- 10-18
- ISSN
- 1744-6872 (ISSN-L)
- OpenAlex
- W4308956492
- Cited by
- 7
- References
- 46
- Citations by year
- 2026: 4 · 2025: 2 · 2024: 1
- FWCI
- 0.31
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Pharmacogenetics and Genomics (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Canadian Institutes of Health Research (80361_1)
- Topics
- Health Sciences › Medicine › Oncology › Drug Transport and Resistance Mechanisms
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Pharmacogenetics and Drug Metabolism
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Interaction Studies and Fluorescence Analysis
- Keywords
- tamoxifen, endoxifen, OATP1A2, OATP1B1, P-glycoprotein, ABCG2, drug transporters, adverse drug reactions, dizziness, SLCO2B1, SLCO1A2, SLCO1B1, breast cancer, pharmacogenetics, plasma drug concentration, blood-brain barrier
- MeSH terms
- ATP Binding Cassette Transporter, Subfamily G, Member 2, Breast Neoplasms, Female, Humans, Neoplasm Proteins, Tamoxifen, ATP Binding Cassette Transporter, Subfamily B, ATP Binding Cassette Transporter, Subfamily B, Member 1, Organic Anion Transporters, Liver-Specific Organic Anion Transporter 1, HEK293 Cells, Drug-Related Side Effects and Adverse Reactions
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Impact of organic anion transporting polypeptide, P-glycoprotein, and breast cancer resistance protein transporters on observed tamoxifen and endoxifen concentration and adverse effects. https://app.cochat.ai/papers/10.1097/fpc.0000000000000486
- The paper
- Keller, D. N., Medwid, S. J., Ross, C. D., Wigle, T. J., & Kim, R. B. (2023). Impact of organic anion transporting polypeptide, P-glycoprotein, and breast cancer resistance protein transporters on observed tamoxifen and endoxifen concentration and adverse effects. Pharmacogenetics and Genomics. https://doi.org/10.1097/fpc.0000000000000486
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.